Iris Pharma, an ophthalmic preclinical and clinical CRO, and RxGen, a specialty preclinical CRO focused on the development and application of translational research models, have established a strategic alliance to offer fully integrated “bench-to-bedside” ophthalmology research services to the global pharmaceutical and biotechnology industries. Iris Pharma will offer immediate access to RxGen’s nonhuman primate ophthalmic research models and related preclinical in vivo services, via a flexible engagement model.
“Our alliance with RxGen is an exciting development for both companies. For Iris Pharma, this relationship allows us to add RxGen’s unique capabilities and expertise to our existing portfolio of research and development services, completing the full value-chain required to bring a drug from bench to bedside,” said Pierre-Paul Elena, chief executive officer of Iris Pharma.
“Effectively translating discovery to approved therapeutic demands time and cost efficient program design and management, capitalizing on the best available preclinical test systems while maintaining a clear eye on the clinical pathway,” said Matthew Lawrence, chief executive officer of RxGen. “We look forward to working with Iris Pharma to match capabilities with needs to provide the lowest risk, highest return translational research solutions.”